Discover Camcevi.
site-logo
AVAILABLE
TO ORDER
 

Don’t sweat
the coverage1,2

Don’t sweat the coverage1,2

96%

patients covered by

Medicare*

91%

patients covered by

Commercial*

Please contact your patient’s health plan or submit benefits verification. Actual coverage could vary based on the member’s benefit design.

*As of 11/07/23.
Coverage is not indicative of utilization management criteria.

Formulary
Coverage Finder

The formulary coverage tool below can help check CAMCEVI® coverage for various plans. Coverage varies by type and plan.

Check patient coverage

DON’T SWEAT THE CO-PAY

Eligible patients may pay as little as:
$0 Co-Pay
per Camcevi treatment
Learn more

Learn More About CAMCEVI

CAMCEVI Syringe

Learn More About CAMCEVI

Frequently asked questions
Accord Cares

CARE THAT GOES
BEYOND TREATMENT

Because we care, there’s AccordCaresTM: key support and resources for patients in need.

Get support Download Enrollment FormDownload Enrollment Form

Review and download
the Patient Brochure

Accord Cares Download Enrollment FormIn English
Accord Cares Download Enrollment FormEn español

Due to recent changes to coding requirements, you may be required to add new modifiers to Medicare claim forms.

Download coding tip sheetDownload tip sheet

CAMCEVI received pass-through status effective October 1, 2022.*
Payment instructions now available in Oct. 2022 OPPS update.

Download BillingDownload billing &
reimbursement guide

*CMS Status Indicator = G (Pass-through Drugs and Biologicals).

    ×

    *CMS Status Indicator = G (Pass-through Drugs and Biologicals).

    DON’T SWEAT INVENTORY MANAGEMENT

    Stay steps ahead of your inventory with AccordConnects™

    Visit accordconnects.com or

    Download the app
    Accord-Connects-iphone

    DON’T SWEAT YOUR ORDER

    We are constantly working to expand our network of distribution partners and GPOs to make your job easier.

    Distribution Partners

    Name
    Amerisource SD
    Telephone
    800.543.2111
    Order Link
    Besse Online
    Name
    Besse Medical
    Telephone
    800.543.2111
    Order Link
    Besse Online
    Name
    Cardinal SD
    Telephone
    855.855.0708
    Order Link
    Specialty Online
    Name
    McKesson MSCD Oncology Multispecialty
    Telephone
    800.482.6700
    855.477.9800
    Order Link
    MSCD Online
    Name
    McKesson MPB
    Telephone
    877.625.2566
    Order Link
    McKesson Connect

    GPO Partners

    Name
    UROGPO
    Telephone
    404.250.3568
    Order Link
    Order Online
    Name
    International Urology Network (IUN)
    Telephone
    800.543.2111
    Name
    VitalSource™ GPO
    Telephone
    877.453.3972
    Order Link
    Specialty Online
    Unity and OnMark GPOs: Information for Oncology Network and specialty practice groups can be found on McKesson’s Customer Portal.

    HAVE A QUESTION?

    Let us simplify it for you.

    CONNECT WITH A REPRESENTATIVE

      GET UPDATES

      Stay informed about
      CAMCEVI with regular updates,
      education, and more.

      *Required fields

      IMPORTANT SAFETY INFORMATION

      Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.

      CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction, spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.

      Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

      Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.

      Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and according to current clinical practice.

      Androgen deprivation therapy may prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes.

      Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.

      Monitor serum levels of testosterone following injection of CAMCEVI.

      Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.

      The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.

      INDICATION

      CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.

      Click here for full Prescribing Information.

      References:

      1. Data on file. Accord BioPharma; 2023. 2. Data on file. Accord BioPharma; 2023.